Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $72.
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $72.